Novo Nordisk Black and White

Novo Nordisk Skeptic Finally Upgrades Stock

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Markets Insider · 1d

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Seeking Alpha on MSN · 1d

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ diabetes drugs,

10d

South African watchdog probes Novo Nordisk and Sanofi over insulin

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

New York Post9d

Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

9don MSN

Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It

Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...

USA Today9d

Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results